About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
A study was conducted to assess the association between health care costs and patient adherence to aminosalicylate pharmacotherapy for digestive disorders.
Fadia T. Shaya, PhD, MPH, Antoine C. El Khoury, PhD, Winston Wong, PharmD, Nevin Whitelaw, BSc, George Whitelaw, RPh, Raymond E. Joseph, MD, and Russell D. Cohen, MD
The Neurotoxin Spasticity Consensus Group presents its findings on botulinum toxin in the treatment of various conditions characterized by muscle overactivity.
Thomas L. Davis, MD, Matthew A. Brodsky, MD, Victoria A. Carter, MD, Marc DiFazio, MD, Ben Frishberg, MD, Eugene C. Lai, MD, PhD, John McGuire, MD, Douglas P. Meyer, RPh, Jill L. Ostrem, MD, Aliya I. Sarwar, MD, and Kevin White, MD
The safety and efficacy of ACE-inhibitors (ramipril, perindopril, and trandolapril), an angiotensin-receptor blocker (valsartan), an anticoagulant/antiplatelet combination, and a direct renin inhibitor (aliskiren) are reviewed.
Reuben B. David
The authors report on ceftaroline for skin and skin-structure infections; cethromycin for acute bacterial exacerbations of chronic bronchitis; tigecycline for community-acquired pneumonia; ceftobiprole for skin infections; moxifloxacin for leprosy; telithromycin for acute bacterial sinusitis; oseltamivir to reduce pneumonia risk following pediatric influenza; a human papillomavirus vaccine; and micafungin for invasive candidiasis in children.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Three agents are discussed: posaconazole oral suspension (Noxafil) for Aspergillus and Candida infections; Travoprost Z ophthalmic solution (Travatan Z), for glaucoma or ocular hypertension; and arformoterol tartrate inhalation solution (Brovana) for obstructive pulmonary disease, chronic bronchitis, and emphysema.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, discusses the advantages of electronic medical records and the forthcoming development of linked registries that hold promise for improving outcomes for patients with chronic disease.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, reports on the results of a survey about the role of appropriate interventions for preventing clinical errors.
Matthew Grissinger, RPh, FASCP
A First Step Toward Measuring Pharmacy Performance: Will the Pharmacy Quality Alliance Lead the Way?
Stephen Barlas discusses the Pharmacy Quality Alliance, a collaboration to develop new strategies for measuring pharmacy performance, with the goal of improving patient outcomes.
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
The authors review anidulafungin (Eraxis) for the treatment of fungal infections.
Priti N. Patel, PharmD, BCPS, and Lisa Charneski, PharmD, BCPS